Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

China · Delayed Price · Currency is CNY

20.27

+0.50 (2.53%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research and Experimental Development	1.17B	-	-			-	-
Pharmaceutical Manufacturing	202.02M	-	-			-	-
Diagnostic Kits / Equipment	-	-	-			268.38M	170.80M
Diagnostic Kits / Equipment Growth	-	-	-			57.13%	-
Total	1.38B	-	-			268.38M	170.80M
Total Growth	-	-	-			57.13%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	1.28B	-	-			262.72M	163.49M
China Growth	-	-	-			60.70%	-
Overseas	101.22M	-	-			4.47M	1.24M
Overseas Growth	-	-	-			261.13%	-
Total	1.38B	-	-			267.19M	164.72M
Total Growth	-	-	-			62.20%	-

Source: S&P Global Market Intelligence.